Pharmacokinetic comparisons of hydroxysafflower yellow A in normal and blood stasis syndrome rats

Journal of Ethnopharmacology

Volumn 129, Issue 1, 2010, Pages 1-4

  Tian, Yun ^a   Yang, Zhi Fu ^a   Li, Yan ^a   Qiao, Yi ^a   Yang, Jing ^a   Jia, Yan Yan ^a   Wen, Ai Dong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Blood stasis syndrome; Hydroxysafflower yellow A; Pharmacokinetics; Safflower extract

Indexed keywords

HERBACEOUS AGENT; HYDROXYSAFFLOWER YELLOW A; SAFFLOWER EXTRACT; UNCLASSIFIED DRUG; CHALCONE; HYDROXYSAFFLOR YELLOW A; PLANT EXTRACT; QUINONE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG UPTAKE; HEMOSTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; CHEMISTRY; CHINESE MEDICINE; CIRCULATION; DIFFERENTIAL DIAGNOSIS; FLOWER; METABOLIC CLEARANCE RATE; ORAL DRUG ADMINISTRATION; RANDOMIZATION; REFERENCE VALUE; SAFFLOWER;

ANIMALIA; CARTHAMUS TINCTORIUS; RATTUS;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BLOOD CIRCULATION; CARDIOVASCULAR DISEASES; CARTHAMUS TINCTORIUS; CHALCONE; DIAGNOSIS, DIFFERENTIAL; FLOWERS; MALE; MEDICINE, CHINESE TRADITIONAL; METABOLIC CLEARANCE RATE; PLANT EXTRACTS; QUINONES; RANDOM ALLOCATION; RATS; REFERENCE VALUES;

EID: 77951942178     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2010.02.023     Document Type: Article

References (23)

1. Bensky D., Gamble A. Chinese Herbal Medicine Materia Medica, Revised Edition 1993, Eastland Press, Washington, pp. 265-266.
2. Chiu C.C., Lan C.Y., Chang Y.H. Objective assessment of blood stasis using computerized inspection of sublingual veins. Computer Methods and Programs in Biomedicine 2002, 69:1-12.
3. Chu D.F., Liu W.H., Huang Z., Liu S.S., Fu X.Q., Liu K. Pharmacokinetics and excretion of hydroxysafflor yellow A, a potent neuroprotective agent from safflower, in rats and dogs. Planta Medicine 2006, 72:418-423.
4. Directive 86/609/EEC on the Protection of Animals Used for Experimental and Other Scientific Purposes, 1986. European Commission.
5. Fan L., Zhao H.Y., Xu M., Zhou L., Guo H., Han J., Wang B.R., Guo D.A. Qualitative evaluation and quantitative determination of 10 major active components in Carthamus tinctorius L. by high-performance liquid chromatography coupled with diode array detector. Journal of Chromatography A 2009, 1216:2063-2070.
6. Jinwey The population pharmacology research on pharma and cokinetics of drugs. Pharmazie 1996, 46:623-629.
7. Li Y., Zhang Z.Y., Zhang J.L. Determination of hydroxysafflor yellow A in rat plasma and tissues by high-performance liquid chromatography after oral administration of safflower extract or safflor yellow. Biomedical Chromatography 2007, 21:326-334.
8. Liang X.T. Basic Study of Common Chinese Medicine. Part II 2004, Science Press, Beijing, pp. 102-115.
9. Pfeifrs S. The effect of disease on the pharmacokinetics of drugs. Kidney Disease Pharmazie 1991, 46:305-312.
10. Pfeifrs S. The effect of disease on the pharmacokinetics of drugs 1. Pharmazie 1991, 46:830.
11. Pfeifrs S. The effect of disease states on pharmacokinetics of drugs 2. Liver Biliary Disease Pharmazie 1991, 46:623-628.
12. Qi J.P., Jin X.F., Huang L.S., Ping Q.N. Simultaneous determination of hydroxysafflor yellow A and ferulic acid in rat plasma after oral administration of the co-extractum of Rhizoma chuanxiong and Flos Carthami by HPLC-diode array detector. Biomedical Chromatography 2007, 21:816-822.
13. Ren P., Huang X., Li S.Q. Pharmacokinetic characteristics of ferulic acid in patients with different syndromes of deficiency of spleen qi, stagnation of liver qi and spleen deficiency, and excess of stomach heat. Journal of Chinese Integrative Medicine 2006, 4:147-151.
14. The State Pharmacopoeia Commission of China Pharmacopoeia of the People's Republic of China, Part I 2005, Chemical Industry Press, Beijing, China, p. 10.
15. Tian Z.M. The development of blood concentration measurement on the syndrome of Chinese formula and efficacy determination. Foreign Medical Sciences 1989, 10:58-59.
16. Wei X.B., Liu H.Q., Sun X., Fu F.H., Zhang X.M., Wang J., An J., Ding H. Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action. Neuroscience Letters 2005, 386:58-62.
17. Wen A.D., Huang X., Jiang Y.P., et al. Blood stasis in congestive heart failure bears relation with digoxin clinical pharmacokinetics. Journal of Fourth Mililitary Medical University 2001, 22:631-634.
18. Yang Z.F., Wen A.D., Mei Q.B., et al. Pharmacokinetical study of safflor yellow on rat acute model of blood stasis syndrome. Journal of Chinese Medicinal Materials 2001, 24:730-732.
19. Yang Z.F., Yang J., Jia Y.Y., Tian Y., Wen A.D. Pharmacokinetic properties of hydroxysafflor yellow A in healthy Chinese female volunteers. Journal of Ethnopharmacology 2009, 124:635-638.
20. Yu Z.G., Gao X.X., Zhao Y.L., Bi K.S. HPLC determination of safflor yellow A and three active isoflavones from TCM Naodesheng in rat plasma and tissues and its application to pharmacokinetic studies. Biomedical Chromatography 2007, 21:577-584.
21. Zhao H., Wu W., Zheng Y.L., Wei Y.M., Yang Y.X. Genetic diversity of Carthamus tinctorius L. based on RAMP Markers. Journal of Plant Genetic Resources 2007, 8:64-67.
22. Zhu H.B., Wang Z.H., Ma C.J., Tian J.W., Fu F.H., Li C.L., Guo D., Roder E., Liu K. Neuroprotective effects of hydroxysafflor yellow A in vivo and in vitro studies. Planta Medicine 2003, 69:429-433.
23. Zhu H.B., Wang Z.H., Tian J.W., Fu F.H., Liu K., Li C.L. Protective effect of hydroxysafflor yellow A on experimental cerebral ischemia in rats. Acta Pharmaceutica Sinica 2005, 40:1144-1146.